Background: Feature selection, as a preprocessing stage, is a challenging problem in various sciences such as biology, engineering, computer science, and other fields. For this purpose, some studies have introduced tools and softwares such as WEKA. Meanwhile, these tools or softwares are based on filter methods which have lower performance relative to wrapper methods. In this paper, we address this limitation and introduce a software application called FeatureSelect. In addition to filter methods, FeatureSelect consists of optimisation algorithms and three types of learners. It provides a user-friendly and straightforward method of feature selection for use in any kind of research, and can easily be applied to any type of balanced and unbalanced data based on several score functions like accuracy, sensitivity, specificity, etc. Results: In addition to our previously introduced optimisation algorithm (WCC), a total of 10 efficient, well-known and recently developed algorithms have been implemented in FeatureSelect. We applied our software to a range of different datasets and evaluated the performance of its algorithms. Acquired results show that the performances of algorithms are varying on different datasets, but WCC, LCA, FOA, and LA are suitable than others in the overall state. The results also show that wrapper methods are better than filter methods. Conclusions: FeatureSelect is a feature or gene selection software application which is based on wrapper methods. Furthermore, it includes some popular filter methods and generates various comparison diagrams and statistical measurements.
Alzheimer's disease (AD) is a chronic neurodegenerative disorder. It is the most common type of dementia that has remained as an incurable disease in the world, which destroys the brain cells irreversibly. In this study, a systems biology approach was adopted to discover novel micro-RNA and gene-based biomarkers of the diagnosis of Alzheimer's disease. The gene expression data from three AD stages (Normal, Mild Cognitive Impairment, and Alzheimer) were used to reconstruct co-expression networks. After preprocessing and normalization, Weighted Gene Co-Expression Network Analysis (WGCNA) was used on a total of 329 samples, including 145 samples of Alzheimer stage, 80 samples of Mild Cognitive Impairment (MCI) stage, and 104 samples of the Normal stage. Next, three gene-miRNA bipartite networks were reconstructed by comparing the changes in module groups. Then, the functional enrichment analyses of extracted genes of three bipartite networks and miRNAs were done, respectively. Finally, a detailed analysis of the authentic studies was performed to discuss the obtained biomarkers. The outcomes addressed proposed novel genes, including MBOAT1, ARMC7, RABL2B, HNRNPUL1, LAMTOR1, PLAGL2, CREBRF, LCOR, and MRI1and novel miRNAs comprising miR-615-3p, miR-4722-5p, miR-4768-3p, miR-1827, miR-940 and miR-30b-3p which were related to AD. These biomarkers were proposed to be related to AD for the first time and should be examined in future clinical studies. Alzheimer is an incurable neurological disorder and is classified as an aging disease. It is one of the important neurological complications which can affect the whole society ranging from the patients themselves to the people who are around them. The aging population is growing in many countries, and the treatment costs of Alzheimer are dramatically high. These issues have drawn the attention of many researchers to the importance of the examination of this disease 1. There are many organizations all over the world which work in the field of early diagnosis and prevention of Alzheimer 2,3. National center for health statistics considers Alzheimer's disease as the sixth cause of death in the United States 4. As a result, Alzheimer's disease is among the costliest diseases for various socioeconomic classes. As the population of the world grows, the number of inflicted people increases. Therefore, the control of the affected population becomes more difficult 5. Significant advances in medical and neurological sciences have led to a longer life expectancy and have increased the number of Alzheimer's disease patients. Ultimately, the prevention of disease before its occurrence is regarded to be one of the most important pillars of treatment at different stages of this disease. Treatment or postponement of a disease depends on its discovery by identifying the biological pathways involved in the disease and adopting various drug-disease network approaches 6 to control these pathways. In recent decades, deep investigation of molecular mechanisms has become more prevalent as a researc...
Background The coronavirus disease-19 (COVID-19) emerged in Wuhan, China and rapidly spread worldwide. Researchers are trying to find a way to treat this disease as soon as possible. The present study aimed to identify the genes involved in COVID-19 and find a new drug target therapy. Currently, there are no effective drugs targeting SARS-CoV-2, and meanwhile, drug discovery approaches are time-consuming and costly. To address this challenge, this study utilized a network-based drug repurposing strategy to rapidly identify potential drugs targeting SARS-CoV-2. To this end, seven potential drugs were proposed for COVID-19 treatment using protein-protein interaction (PPI) network analysis. First, 524 proteins in humans that have interaction with the SARS-CoV-2 virus were collected, and then the PPI network was reconstructed for these collected proteins. Next, the target miRNAs of the mentioned module genes were separately obtained from the miRWalk 2.0 database because of the important role of miRNAs in biological processes and were reported as an important clue for future analysis. Finally, the list of the drugs targeting module genes was obtained from the DGIDb database, and the drug-gene network was separately reconstructed for the obtained protein modules. Results Based on the network analysis of the PPI network, seven clusters of proteins were specified as the complexes of proteins which are more associated with the SARS-CoV-2 virus. Moreover, seven therapeutic candidate drugs were identified to control gene regulation in COVID-19. PACLITAXEL, as the most potent therapeutic candidate drug and previously mentioned as a therapy for COVID-19, had four gene targets in two different modules. The other six candidate drugs, namely, BORTEZOMIB, CARBOPLATIN, CRIZOTINIB, CYTARABINE, DAUNORUBICIN, and VORINOSTAT, some of which were previously discovered to be efficient against COVID-19, had three gene targets in different modules. Eventually, CARBOPLATIN, CRIZOTINIB, and CYTARABINE drugs were found as novel potential drugs to be investigated as a therapy for COVID-19. Conclusions Our computational strategy for predicting repurposable candidate drugs against COVID-19 provides efficacious and rapid results for therapeutic purposes. However, further experimental analysis and testing such as clinical applicability, toxicity, and experimental validations are required to reach a more accurate and improved treatment. Our proposed complexes of proteins and associated miRNAs, along with discovered candidate drugs might be a starting point for further analysis by other researchers in this urgency of the COVID-19 pandemic.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.